Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR - ICR / Cancer Res. Society Partnership-Res. Gr. -Non-melanoma skin cancers

Université de Sherbrooke

$60,000.00

Development of NF1 Gene Therapy

EF 2021-22

Résumé
Neurofibromatosis type I is an incurable genetic disease. Patients develop disfiguring tumors that are often difficult to remove by surgery and may be fatal. This disease is caused by a genetic mutation in the gene producing neurofibromin, rendering it non-functional. The idea here is to test the hypothesis that re-expressing functional neurofibromin in these tumors would lead to tumor regression or better tissue normalization. To do so, we will engineer a novel mouse model with inducible expression of neurofibromin. We will also develop a general drug-like strategy aiming at restoring functional neurofibromin.
Programme
CIHR - ICR / Cancer Res. Society Partnership-Res. Gr. -Non-melanoma skin cancers
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
468132
Name
Brosseau Jean-Philippe
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Development of NF1 Gene Therapy
Programtype2
Operating Grants
Orgnameinp2
Université de Sherbrooke
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Res. Society Partnership-Res. Gr. -Non-melanoma skin cancers
Keyworddelim
Brain And Nervous System; Childhood And Young Adult ; Oncogenes And Tumour Suppressors
Abstract
Neurofibromatosis type I is an incurable genetic disease. Patients develop disfiguring tumors that are often difficult to remove by surgery and may be fatal. This disease is caused by a genetic mutation in the gene producing neurofibromin, rendering it non-functional. The idea here is to test the hypothesis that re-expressing functional neurofibromin in these tumors would lead to tumor regression or better tissue normalization. To do so, we will engineer a novel mouse model with inducible expression of neurofibromin. We will also develop a general drug-like strategy aiming at restoring functional neurofibromin.
Competitiondate
202202
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Brosseau, Jean-Philippe
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Musculoskel Hlth &Arth~ $60,000~ $0~